<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:hpo ids='HP_0003613'>Antiphospholipid antibodies</z:hpo> (APLA) are established risk factors for <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> but their role in the pathogenesis of <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> is unclear </plain></SENT>
<SENT sid="1" pm="."><plain>The purpose of the present study was to evaluate the relevance of various APLA in patients with cryptogenic <z:hpo ids='HP_0001297'>stroke</z:hpo> (group A, n = 21) and determined causes of <z:hpo ids='HP_0001297'>stroke</z:hpo> (group B, n = 104) according to the TOAST classification in comparison with healthy volunteers without any thrombotic or ischaemic event in their history (group C, n = 84) </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Median ages were 52 yr (A), 60 yr (B) and 51 yr (C) </plain></SENT>
<SENT sid="3" pm="."><plain>Blood samples were tested for <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> (LA) using <z:chebi fb="0" ids="16247">phospholipid</z:chebi>-dependent coagulation tests (activated partial thromboplastin time, diluted Russell viper venom time) </plain></SENT>
<SENT sid="4" pm="."><plain>Confirmatory tests were performed if necessary </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, we assessed the presence of specific APLA and their antibody subclasses against <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> (AclA), phosphatidylserine (ApsA), phosphatidylinositol (ApiA) and beta-2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I (Abeta2A) using enzyme-linked immunosorbent assay </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: For ApsA IgG we found a significantly higher prevalence in <z:hpo ids='HP_0001297'>stroke</z:hpo> patients (57.7%) compared with <z:mpath ids='MPATH_458'>normal</z:mpath> subjects (4.8%; P &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>Similarly, Abeta2A IgA was significantly more prevalent in <z:hpo ids='HP_0001297'>stroke</z:hpo> patients (20.8%) in comparison with <z:mpath ids='MPATH_458'>normals</z:mpath> (3.6%; P &lt; 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>For <z:hpo ids='HP_0000001'>all</z:hpo> other APLAs tested, no significant differences emerged after adjustment for multiple comparisons </plain></SENT>
<SENT sid="9" pm="."><plain>We did not find significant differences between <z:hpo ids='HP_0001297'>stroke</z:hpo> subtypes for any APLA </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: The results of this study suggest a relevant role for antiphosphatidylserine IgG and anti-beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I IgA in <z:hpo ids='HP_0001297'>stroke</z:hpo> aetiology </plain></SENT>
</text></document>